Andy Hall

Andy Hall is the Chief Scientific Officer at RareCan, where they work on facilitating research into rare forms of cancer. With a background in haematology and a focus on childhood leukaemia, they have extensive experience in the medical field, including roles at the Human Tissue Authority, the NHS, and Newcastle University. Their research interests include drug resistance mechanisms in childhood leukaemia, national standards for biobanking, and running national biobanks for cancer patients. Andy Hall is also involved in various medical and pathology fellowships and memberships, demonstrating a commitment to advancing their knowledge and expertise in the field.